文献速递急性肾损伤

肾细胞特异性纳米疗法改善急性肾损伤

Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury.
PubMed 文献 · Kidney Int · 2024-07-25

本研究开发了一种由cilastatin和地塞米松复合的H-Dot纳米药物,可特异性靶向肾脏近端小管上皮细胞。该纳米药物在血浆pH下稳定、尿pH下释放,体内主要分布于肾脏和膀胱,尿回收率75%,全身毒性低于游离地塞米松。在横纹肌溶解和双侧缺血再灌注两种AKI小鼠模型中,该纳米药物改善肾功能并减轻肾细胞损伤。

要点

  • cilastatin复合赋予纳米药物肾脏近端小管上皮细胞特异性。
  • 纳米药物在尿pH下释放,尿回收率75%,全身毒性低于游离地塞米松。
  • 两种AKI小鼠模型中改善肾功能并减轻肾细胞损伤。

核心结论

  • 肾特异性纳米药物搭载地塞米松可保留疗效并减少脱靶分布与毒性。

研究设计与样本

  • 开发并表征由cilastatin、地塞米松和H-Dot构建的纳米药物,在雄性C57BL/6小鼠的横纹肌溶解和双侧缺血再灌注两种AKI模型中评估。

主要发现

  • 纳米药物在血浆pH下稳定,在尿pH下具有释放动力学。
  • 体内特异性生物分布于肾脏和膀胱,尿回收率75%,全身毒性低于天然地塞米松。
  • cilastatin复合在体内赋予肾脏近端小管上皮细胞特异性,并在体外实现地塞米松递送至近端小管上皮细胞核。
  • 在两种AKI小鼠模型中改善肾功能并减少肾细胞损伤。

临床怎么用

  • 该策略可能用于靶向治疗AKI及其他肾脏疾病,但尚未进入临床。

局限性

  • 研究仅基于雄性C57BL/6小鼠的两种AKI模型,未报告临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury (AKI) increases the risk of in-hospital death, adds to expense of care, and risk of early chronic kidney disease. AKI often follows an acute event such that timely treatment could ameliorate AKI and potentially reduce the risk of additional disease. Despite therapeutic success of dexamethasone in animal models, clinical trials have not demonstrated broad success. To improve the safety and efficacy of dexamethasone for AKI, we developed and characterized a novel, kidney-specific nanoparticle enabling specific within-kidney targeting to proximal tubular epithelial cells provided by the megalin ligand cilastatin. Cilastatin and dexamethasone were complexed to H-Dot nanoparticles, which were constructed from generally recognized as safe components. Cilastatin/Dexamethasone/H-Dot nanotherapeutics were found to be stable at plasma pH and demonstrated salutary release kinetics at urine pH. In vivo, they were specifically biodistributed to the kidney and bladder, with 75% recovery in the urine and with reduced systemic toxicity compared to native dexamethasone. Cilastatin complexation conferred proximal tubular epithelial cell specificity within the kidney in vivo and enabled dexamethasone delivery to the proximal tubular epithelial cell nucleus in vitro. The Cilastatin/Dexamethasone/H-Dot nanotherapeutic improved kidney function and reduced kidney cellular injury when administered to male C57BL/6 mice in two translational models of AKI (rhabdomyolysis and bilateral ischemia reperfusion). Thus, our design-based targeting and therapeutic loading of a kidney-specific nanoparticle resulted in preservation of the efficacy of dexamethasone, combined with reduced off-target disposition and toxic effects. Hence, our study illustrates a potential strategy to target AKI and other diseases of the kidney.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Funahashi Y, Park SH, Hebert JF, et al. Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury. Kidney Int. 2024. PMID: 39067856. doi:10.1016/j.kint.2024.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。